Functional characterization of genetic polymorphisms identified in the promoter region of the xanthine oxidase gene

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 6, 2010, Pages 599-604

  Kudo, Mutsumi ^a   Sasaki, Takamitsu ^a   Ishikawa, Masaaki ^a   Hirasawa, Noriyasu ^b   Hiratsuka, Masahiro ^b  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

Genetic polymorphism; Promoter region; Regulation; Xanthine oxidase

Indexed keywords

GENOMIC DNA; XANTHINE OXIDASE;

5' UNTRANSLATED REGION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA FLANKING REGION; GENE EXPRESSION; GENE FREQUENCY; GENE LOCATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; JAPANESE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78951470115     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-NT-054     Document Type: Article

References (27)

1. Pritsos, C. A.: Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem. Biol. Interact., 129: 195-208 (2000).
2. Kitamura, S., Sugihara, K. and Ohta, S.: Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab. Pharmacokinet., 21: 83-98 (2006).
3. Ansari, A., Hassan, C., Duley, J., Marinaki, A., Shobowale- Bakre, E. M., Seed, P., Meenan, J., Yim, A. and Sanderson, J.: Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment. Pharmacol. Ther., 16: 1743-1750 (2002).
4. Xu, P., Huecksteadt, T. P., Harrison, R. and Hoida, J. R.: Molecular cloning, tissue expression of human xanthine dehydrogenase. Biochem. Biophys. Res. Commun., 199: 998-1004 (1994).
5. Saksela, M., Lapatto, R. and Raivio, K. O.: Xanthine oxidoreductase gene expression and enzyme activity in developing human tissues. Biol. Neonate, 74: 274-280 (1998).
6. Guerciolini, R., Szumlanski, C. and Weinshilboum, R. M.: Human liver xanthine oxidase: nature and extent of individual variation. Clin. Pharmacol. Ther., 50: 663-672 (1991).
7. Saruwatari, J., Nakagawa, K., Shindo, J., Tajiri, T., Fujieda, M., Yamazaki, H., Kamataki, T. and Ishizaki, T.: A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin. Pharmacol. Ther., 72: 200-208 (2002).
8. Carrillo, J. A. and Benitez, J.: Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin. Pharmacol. Ther., 55: 293-304 (1994).
9. Simmonds, H. A., Reiter, S. and Nishino, T.: Hereditary xanthinuria. In: Scriver C. R., Beaudet A. L., Sly S. W., Valle D. (ed.): The metabolic and molecular bases of inherited disease. New York: McGraw-Hill Inc., 1995, pp. 1781-1797.
10. Ichida, K., Amaya, Y., Kamatani, N., Nishino, T., Hosoya, T. and Sakai, O.: Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria. J. Clin. Invest., 99: 2391-2397 (1997).
11. Levartovsky, D., Lagziel, A., Sperling, O., Liberman, U., Yaron, M., Hosoya, T., Ichida, K. and Peretz, H.: XDH gene mutation is the underlying cause of classical xanthinuria: a second report. Kidney Int., 57: 2215-2220 (2000).
12. Sakamoto, N., Yamamoto, T., Moriwaki, Y., Teranishi, T., Toyoda, M., Onishi, Y., Kuroda, S., Sakaguchi, K., Fujisawa, T., Maeda, M. and Hada, T.: Identification of a new point mutation in the human xanthine dehydrogenase gene responsible for a case of classical type I xanthinuria. Hum. Genet., 108: 279-283 (2001).
13. Gok, F., Ichida, K. and Topaloglu, R.: Mutational analysis of the xanthine dehydrogenase gene in a Turkish family with autosomal recessive classical xanthinuria. Nephrol. Dial. Transplant., 18: 2278-2283 (2003).
14. Arikyants, N., Sarkissian, A., Hesse, A., Eggermann, T., Leumann, E. and Steinmann, B.: Xanthinuria type I: a rare cause of urolithiasis. Pediatr. Nephrol., 22: 310-314 (2007).
15. Giverhaug, T., Loennechen, T. and Aarbakke, J.: The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX). Gen. Pharmacol., 33: 341-346 (1999).
16. Balis, F. M., Holcenberg, J. S., Zimm, S., Tubergen, D., Collins, J. M., Murphy, R. F., Gilchrist, G. S., Hammond, D. and Poplack, D. G.: The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin. Pharmacol. Ther., 41: 384-387 (1987).
17. Innocenti, F., Danesi R., Di Paolo, A., Loru, B., Favre, C., Nardi, M., Bocci G., Nardini, D., Macchia, P. and Del Tacca, M.: Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother. Pharmacol., 37: 409-414 (1996).
18. Zimm, S., Collins, J. M., O'Neill, D., Chabner, B. A. and Poplack, D. G.: Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin. Pharmacol. Ther., 34: 810-817 (1983).
19. Venkat Raman, G., Sharman, V. L. and Lee, H. A.: Azathioprine and allopurinol: a potentially dangerous combination. J. Intern. Med., 228: 69-71 (1990).
20. Kennedy, D. T., Hayney, M. S. and Lake, K. D.: Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann. Pharmacother., 30: 951-954 (1996).
21. Wong, D. R., Derijks, L. J., den Dulk, M. O., Gemmeke, E. H. and Hooymans, P. M.: The role of xanthine oxidase in thiopurine metabolism: a case report. Ther. Drug Monit., 29: 845-848 (2007).
22. Kudo, M., Moteki, T., Sasaki, T., Konno, Y., Ujiie, S., Onose, A., Mizugaki, M., Ishikawa, M. and Hiratsuka, M.: Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet. Genomics, 18: 243-251 (2008).
23. M., Sasaki, T., Ishikawa, M., Hirasawa, N. and Hiratsuka, M.: Kinetics of 6-thioxanthine metabolism by allelic variants of xanthine oxidase. Drug Metab. Pharmacokinet., in press (2010).
24. Xu, P., LaVallee, P. and Hoidal, J. R.: Repressed expression of the human xanthine oxidoreductase gene. E-box and TATA-like elements restrict ground state transcriptional activity. J. Biol. Chem., 275: 5918-5926 (2000).
25. Xu, P., LaVallee, P. A., Lin, J. J. and Hoidal, J. R.: Characterization of proteins binding to E-box/Ku86 sites and function of Ku86 in transcriptional regulation of the human xanthine oxidoreductase gene. J. Biol. Chem., 279: 16057-16063 (2004).
26. Lin, J., Xu, P., LaVallee, P. and Hoidal, J. R.: Identification of proteins binding to E-Box/Ku86 sites and function of the tumor suppressor SAFB1 in transcriptional regulation of the human xanthine oxidoreductase gene. J. Biol. Chem., 283: 29681-29689 (2008).
27. Chaves, F. J., Corella, D., Blesa, S., Mansego, M. L., Marin, P., Portoles, O., Sorli, J. V., Gonzalez-Albert, V., Tormos, M. C., Garcia-Garcia, A. B., Saez, G. and Redon, J.: Xanthine oxidoreductase polymorphisms: influence in blood pressure and oxidative stress levels. Pharmacogenet. Genomics, 17: 589-596 (2007)